INTAC® impedes preparation for extraction and IV abuse

 

 

INTAC® substantially restricts availability of active ingredient for extraction

Example 1: Amount of API extracted for IV abuse: comparison of different IR opioids formulated with INTAC® 3,4

 

 

 

Read how INTAC® achieves bioequivalence

 

 


References:
1. Bartholomäus J, Schwier S, Brett M, Stahlberg HJ, Galia E, Strothmann K. New abuse deterrent formulation (ADF) technology for immediate-release opioids. Drug Dev Deliv. 2013;13(8):76-81.
2. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(0):206-215.
3. Wening K, Lehrach I, Schwier S. Novel abuse deterrent immediate release tablets and capsules for opioids containing hot-melt extruded pellets based on the INTAC® technology. Poster presented at: AAPS Annual Meeting 2015; Orlando, FL.
4. Schwier S, Wening K, Stahlberg H. Comparison of in-vitro test characterization of immediate and extended release products with abuse deterrent features. Poster presented at: PAINWeek 2015; Las Vegas, NV.

 

INTAC®